Oncolytics Biotech

ONCY NASDAQ
1.620
+0.020
+1.25%
已收盘, 16:00 07/16 EDT
开盘
1.640
昨收
1.600
最高
1.700
最低
1.620
成交量
4.26万
成交均量(3M)
4.58万
52周最高
5.47
52周最低
1.572
换手率
0.21%
市值
3,288.35万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Oncolytics Biotech ONCY股票价格,Oncolytics Biotech股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
展开 >

最近浏览

名称
价格
涨跌幅